Literature DB >> 15948240

Expression and immunoreactivity of an epitope of HCV in a foreign epitope presenting system.

Mei Peng1, Chang-Bai Dai, Yuan-Ding Chen.   

Abstract

AIM: To construct and highly express an epitope of hepatitis C virus (HCV) in a foreign epitope presenting vector based on an insect virus, and to study the antigenicity of the epitope.
METHODS: The HCV epitope sequence (amino acid residues 315 to 328: EGHRMAWDMMMNWS) of the E1 region was constructed at different positions of a foreign epitope presenting vector based on an insect virus, flock house virus (FHV) capsid protein encoding gene as a vector, and expressed in E. coli cells. Western blotting and ELISA were used to detect the immunoreactivity of these recombinant proteins.
RESULTS: The gene encoding of the concerned B-cell epitope of HCV E1 envelope protein was expressed on FHV capsid carrier protein at positions I1 (aa 106), I2 (aa 153) and I3 (aa 305), respectively, on the surface of FHV capsid protein. The recombinant proteins in this system could be highly expressed in more than 40% of total cell protein of E. coli BL21. All the expressed recombinant proteins were in inclusion body form, and showed obvious immunoreactivity by Western blotting. Further purified recombinant proteins were detected by indirect ELISA as coating antigen respectively. All recombinant proteins could still show immunoreactivity.
CONCLUSION: The epitope of HCV E1 envelope protein can be highly expressed in FHV carrier system as a chimeric protein with high immunoreactivity. This system has multiple entry sites conferring many possible conformations closer to the native one for a given sequence.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15948240      PMCID: PMC4315989          DOI: 10.3748/wjg.v11.i22.3363

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  24 in total

1.  Accuracy of perceptions of hepatitis B and C status. Injecting drug users need vaccination against hepatitis B.

Authors:  M E Ramsay; M A Balogun; C G Teo; P P Mortimer
Journal:  BMJ       Date:  2000-02-19

2.  Characterization of a V3 domain-specific neutralizing human monoclonal antibody that preferentially recognizes non-syncytium-inducing human immunodeficiency virus type 1 strains.

Authors:  M Schutten; J P Langedijk; A C Andeweg; R C Huisman; R H Meloen; A D Osterhaus
Journal:  J Gen Virol       Date:  1995-07       Impact factor: 3.891

Review 3.  Rational use of diagnostic tools in hepatitis C.

Authors:  M Roggendorf; M Lu; H Meisel; M Riffelmann; E Schreier; S Viazov
Journal:  J Hepatol       Date:  1996       Impact factor: 25.083

4.  Detection of antibody against antigen expressed by molecularly cloned hepatitis C virus cDNA: application to diagnosis and blood screening for posttransfusion hepatitis.

Authors:  T Miyamura; I Saito; T Katayama; S Kikuchi; A Tateda; M Houghton; Q L Choo; G Kuo
Journal:  Proc Natl Acad Sci U S A       Date:  1990-02       Impact factor: 11.205

5.  Antigen chimaeras of poliovirus as potential new vaccines.

Authors:  K L Burke; G Dunn; M Ferguson; P D Minor; J W Almond
Journal:  Nature       Date:  1988-03-03       Impact factor: 49.962

Review 6.  Hepatitis C virus: the major causative agent of viral non-A, non-B hepatitis.

Authors:  Q L Choo; A J Weiner; L R Overby; G Kuo; M Houghton; D W Bradley
Journal:  Br Med Bull       Date:  1990-04       Impact factor: 4.291

7.  Peptide immunogen mimicry of putative E1 glycoprotein-specific epitopes in hepatitis C virus.

Authors:  R Ray; A Khanna; L M Lagging; K Meyer; Q L Choo; R Ralston; M Houghton; P R Becherer
Journal:  J Virol       Date:  1994-07       Impact factor: 5.103

8.  Interaction of immune sera with synthetic peptides corresponding to the structural protein region of hepatitis C virus.

Authors:  W M Ching; C Wychowski; M J Beach; H Wang; C L Davies; M Carl; D W Bradley; H J Alter; S M Feinstone; J W Shih
Journal:  Proc Natl Acad Sci U S A       Date:  1992-04-15       Impact factor: 11.205

9.  An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis.

Authors:  G Kuo; Q L Choo; H J Alter; G L Gitnick; A G Redeker; R H Purcell; T Miyamura; J L Dienstag; M J Alter; C E Stevens
Journal:  Science       Date:  1989-04-21       Impact factor: 47.728

Review 10.  Molecular detection of hepatitis C virus: impact of detection methodology on clinical and laboratory correlations.

Authors:  M Krajden
Journal:  Crit Rev Clin Lab Sci       Date:  1995       Impact factor: 6.250

View more
  3 in total

Review 1.  Recent insights into the biology and biomedical applications of Flock House virus.

Authors:  P A Venter; A Schneemann
Journal:  Cell Mol Life Sci       Date:  2008-09       Impact factor: 9.261

Review 2.  Viral nanoparticles and virus-like particles: platforms for contemporary vaccine design.

Authors:  Emily M Plummer; Marianne Manchester
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2010-09-24

3.  Advances in the study of nodavirus.

Authors:  Chean Yeah Yong; Swee Keong Yeap; Abdul Rahman Omar; Wen Siang Tan
Journal:  PeerJ       Date:  2017-09-27       Impact factor: 2.984

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.